One biotech just gave investors the kind of exit everyone dreams about, one industrial tech platform is finally showing it can grow and make money at the same time, and one research company is turning cash flow into dividends. Here’s what’s moving, worth watching, and what not to chase.
Pre-IPO Angle (Sponsored)
When SpaceX goes public, it could hit a $1.5 TRILLION valuation - that would be 3,000 times bigger than Amazon's IPO.
Most investors will be locked out until AFTER the big announcement.
But I've discovered a "backdoor" that lets you grab a pre-IPO stake in SpaceX right now.
I'm revealing the ticker for free.
Futures 📈
Futures are leaning lower to start the week as traders come back to their screens in a cautious mood. Rising bond yields and fresh geopolitical worries are keeping risk appetite in check, and early flows suggest investors are not in a rush to buy the dip just yet.
Want to make sure you never miss a pre-market alert?
Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.
Email’s great. Texts are faster.
You’ll be first in line when the market starts moving.
What to Watch
Earnings (premarket):
Korn Ferry [KFY]
Global Business Travel Group, Inc. [GBTG]
SharpLink, Inc. [SBET]
Heritage Insurance Holdings, Inc. [HRTG]
Earnings (aftermarket):
Hewlett Packard Enterprise Company [HPE]
Caseys General Stores, Inc. [CASY]
Vail Resorts, Inc. [MTN]
Voyager Technologies, Inc. [VOYG]
Kronos Worldwide Inc. [KRO]
Earnings (time not supplied):
Annexon, Inc. [ANNX]
enGene Holdings Inc. [ENGN]
Economic Reports:
CB Employment Trends Index (Feb): 10:00 am
NY Fed 1-Year Consumer Inflation Expectations (Feb): 11:00 am
Biotechnology
Day One’s Biotech Buyout Lights Up the Tape
Day One Biopharmaceuticals [DAWN] just turned into one of those biotech stories where the ending arrives before the middle. The company agreed to be acquired by French drugmaker Servier in a deal valued at about $2.5 billion, with shareholders to be bought out at $21.50 per share.
This is the kind of outcome everyone hopes for. Big pharma is constantly hunting for promising pipelines, especially in rare diseases and oncology, where successful drugs can command strong pricing power. Day One's lead work in paediatric low-grade glioma clearly caught Servier’s attention, and the acquisition gives the French group a ready-made foothold in that niche.
The catch is that once a takeover price is on the table, the excitement tends to cool down. The thrill is in the announcement, not the waiting room.
My Take For You: This is more of a merger-arbitrage situation than a growth trade. If the stock trades meaningfully below the offer price, consider stepping in.
My Verdict: Interesting for deal watchers, but the easy money has likely been made.
Technology
Samsara’s Long March Toward Profit Pays Off
Samsara [IOT] just reminded the market that sometimes the most powerful story is simply getting closer to making money. The industrial software firm has popped over the past week after showing investors it has nearly erased its losses. Net loss for the year shrank to just $9 million from $155 million a year earlier, a progress that tends to grab Wall Street's attention.
Samsara’s path to profit is based on the massive amounts of operational data it collects from trucks, warehouses, and equipment. It uses that data and AI to help companies run those systems more efficiently. When that model scales, the margins should improve fast.
The catch is that investors have heard versions of the “profitability is coming soon” story before. Expectations are now rising along with the share price. With revenue still projected to grow more than 20% this year, progress toward consistent profits must continue.
My Take For You: Strong growth plus improving margins is a powerful combo, but after a 22% jump, the easy trade may already be behind us. Watching for a pullback could be the calmer way to approach it.
My Verdict: A compelling growth story, but now it needs to prove the profitability trend is real. Investors will be watching closely.
Investment Access (Sponsored)
His salary is $400,000 a year.
But his tax returns show he collects up to $250,000 a MONTH from one source.
It's not real estate.
It's not stocks.
Discover what it is... And how you can get in for less than $20
Financial Services
MarketWise Finds Its Cash Flow Groove
MarketWise [MKTW] just delivered the kind of earnings report income investors love to see. The financial research platform posted $83.4 million in fourth-quarter revenue and $14 million in net income. At the same time, billings surged 42% year over year, a sign that demand for its investment research subscriptions is picking up steam again.
What really caught attention, though, was the shareholder-friendly follow-through. Management boosted the regular dividend by 25% and signaled a $1.80 annual payout target for 2026, which yields double digits at current prices. On top of that, the board restarted a $50 million share buyback program, giving investors two different ways to get paid while the business grows.
The interesting twist is how MarketWise is evolving its strategy. Instead of chasing sheer subscriber numbers, the company is focusing on higher spending customers and better margins, even raising prices on many products. With billings beating guidance and cash flow improving sharply, the model is working.
My Take For You: This is a classic cash-generating digital subscription story. If the growth in billings holds up, the market may start viewing it less like a struggling media company and more like a profitable fintech-style platform.
My Verdict: High yield, improving cash flow, and buybacks on the table. Not flashy, but increasingly hard for income investors to ignore.
Poll: If cash disappeared tomorrow, what would people miss most?
Movers and Shakers
Live Nation Entertainment Inc. [LYV] Premarket Move: +7.21%
Live Nation continues to trade strongly despite facing an antitrust trial before the Department of Justice.
My Take: The jury is out on what the DOJ investigation will mean for LYV, with a possible breakup of the company on the table. If you're chasing momentum, this could be a short-term play.
Cheniere Energy, Inc. [LNG] Premarket Move: +3.37%
Cheniere Energy is pressing higher after confirming plans to expand its Corpus Christi LNG terminal, the second-largest LNG export project in the country.
My Take: LNG is tied closely to the global appetite for natural gas exports, and right now that story still has wind at its back. Wait for a pullback and scale in slowly rather than buying into the first burst of momentum.
Marriott Vacations Worldwide Corp. [VAC] -3.44%
Marriott Vacations is slipping in premarket trading as investors take a step back from travel names after a strong run. Nothing dramatic here, just a bit of profit-taking in a stock that has already had a solid stretch.
Travel demand is still holding up, but these stocks tend to wobble whenever investors start worrying about consumer spending or the broader economy.
My Take: A small dip like this is more noise than panic. If you like the long-term travel story, wait to see if it finds support after the open before thinking about stepping in.
Mounting Pressure (Sponsored)
Big Oil may be facing its biggest challenge yet.
A breakthrough tied to an MIT-trained scientist could unlock a fuel source that’s virtually unlimited.
According to the U.S. Department of Energy, it could last billions of years.
Once operational, the fuel itself costs nothing.
That’s why this story matters now.
Get the full details here.
Everything Else
Energy analysts say the sky is the limit for oil prices as fears of a prolonged shutdown of crude production in the Strait of Hormuz grow.
NVIDIA has invested in Nscale, an AI data center startup now valued at $14.6 billion.
Agilent Technologies has agreed to acquire clinical pathology business Biocare Medical in an all-cash transaction valued at $950 million.
Hims and Hers and Novo Nordisk are said to be on the brink of signing a partnership agreement, ending their legal fight.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
